IL201569A0 - 2-pyridine carboxamide derivatives as sodium channel modulators - Google Patents

2-pyridine carboxamide derivatives as sodium channel modulators

Info

Publication number
IL201569A0
IL201569A0 IL201569A IL20156909A IL201569A0 IL 201569 A0 IL201569 A0 IL 201569A0 IL 201569 A IL201569 A IL 201569A IL 20156909 A IL20156909 A IL 20156909A IL 201569 A0 IL201569 A0 IL 201569A0
Authority
IL
Israel
Prior art keywords
sodium channel
channel modulators
carboxamide derivatives
pyridine carboxamide
pyridine
Prior art date
Application number
IL201569A
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of IL201569A0 publication Critical patent/IL201569A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
IL201569A 2007-05-03 2009-10-15 2-pyridine carboxamide derivatives as sodium channel modulators IL201569A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91574507P 2007-05-03 2007-05-03
US95753607P 2007-08-23 2007-08-23
PCT/IB2008/001050 WO2008135826A2 (en) 2007-05-03 2008-04-21 2 -pyridine carboxamide derivatives as sodium channel modulators

Publications (1)

Publication Number Publication Date
IL201569A0 true IL201569A0 (en) 2010-05-31

Family

ID=39855225

Family Applications (1)

Application Number Title Priority Date Filing Date
IL201569A IL201569A0 (en) 2007-05-03 2009-10-15 2-pyridine carboxamide derivatives as sodium channel modulators

Country Status (33)

Country Link
US (1) US8134007B2 (en)
EP (1) EP2183241B1 (en)
JP (1) JP4657384B2 (en)
KR (1) KR20100007956A (en)
CN (1) CN101675040A (en)
AP (1) AP2516A (en)
AR (1) AR070636A1 (en)
AU (1) AU2008247102B2 (en)
BR (1) BRPI0810202A2 (en)
CA (1) CA2684105C (en)
CL (1) CL2008001268A1 (en)
CO (1) CO6251367A2 (en)
CR (1) CR11061A (en)
CU (1) CU23846B1 (en)
DO (1) DOP2009000254A (en)
EA (1) EA015952B1 (en)
EC (1) ECSP099710A (en)
ES (1) ES2398606T3 (en)
GE (1) GEP20125379B (en)
GT (1) GT200900280A (en)
IL (1) IL201569A0 (en)
MA (1) MA31419B1 (en)
MX (1) MX2009011816A (en)
NI (1) NI200900192A (en)
NZ (1) NZ581614A (en)
PA (1) PA8779201A1 (en)
PE (1) PE20090730A1 (en)
SV (1) SV2009003400A (en)
TN (1) TN2009000450A1 (en)
TW (1) TWI375675B (en)
UY (1) UY31063A1 (en)
WO (1) WO2008135826A2 (en)
ZA (1) ZA200907609B (en)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8012976B2 (en) 2008-08-06 2011-09-06 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
WO2010079443A1 (en) 2009-01-12 2010-07-15 Pfizer Limited Sulfonamide derivatives
CN101638352B (en) * 2009-08-14 2011-08-31 大连理工大学 Aryl-replaced nitrogen heterocyclic compound preparation method
WO2011077313A1 (en) 2009-12-22 2011-06-30 Pfizer Inc. Piperidinecarboxamides as mpges - 1 inhibitors
TW201139406A (en) * 2010-01-14 2011-11-16 Glaxo Group Ltd Voltage-gated sodium channel blockers
CN101768036B (en) * 2010-01-23 2013-05-08 大连理工大学 Method for preparing heterocyclic aromatic compound replaced by aryl in alcohol solvent
EP2531033A4 (en) 2010-02-03 2013-07-31 Biomarin Pharm Inc Dihydropyridophthalazinone inhibitors of poly(adp-ribose) polymerase (parp) for use in treatment of diseases associated with a pten deficiency
KR101826652B1 (en) 2010-02-08 2018-02-07 메디베이션 테크놀로지즈, 인크. Processes of synthesizing dihydropyridophthalazinone derivatives
EP2539358A1 (en) 2010-02-25 2013-01-02 Pfizer Limited Peptide analogues
US9096558B2 (en) 2010-07-09 2015-08-04 Pfizer Limited N-sulfonylbenzamide compounds
CA2804593C (en) 2010-07-09 2015-11-24 Pfizer Limited Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors
EP2593427B1 (en) 2010-07-12 2014-12-24 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
US9102621B2 (en) 2010-07-12 2015-08-11 Pfizer Limited Acyl sulfonamide compounds
CA2801032A1 (en) 2010-07-12 2012-01-19 Pfizer Limited N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
US8772343B2 (en) 2010-07-12 2014-07-08 Pfizer Limited Chemical compounds
US9096500B2 (en) 2010-07-12 2015-08-04 Pfizer Limited Acyl sulfonamide compounds
WO2012007836A1 (en) 2010-07-16 2012-01-19 Purdue Pharma .Lp. Pyridine compounds as sodium channel blockers
CN106478497B (en) * 2010-10-18 2020-05-08 拉夸里亚创药株式会社 Arylamine derivatives as TTX-S blockers
SG10201710578TA (en) 2010-10-21 2018-02-27 Medivation Technologies Inc Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt
WO2012095781A1 (en) 2011-01-13 2012-07-19 Pfizer Limited Indazole derivatives as sodium channel inhibitors
WO2012120398A1 (en) 2011-03-04 2012-09-13 Pfizer Limited Aryl substituted carboxamide derivatives as trpm8 modulators
MA35024B1 (en) 2011-04-05 2014-04-03 Pfizer Ltd PYRROLO- [2,3-D] PYRIMIDINE DERIVATIVES AS INHIBITORS OF TROPOMYOSIN-RELATED KINASES
EP2731959B1 (en) 2011-07-13 2016-02-03 Pfizer Limited Enkephalin analogues
WO2013054185A1 (en) 2011-10-13 2013-04-18 Pfizer, Inc. Pyrimidine and pyridine derivatives useful in therapy
WO2013061205A2 (en) 2011-10-26 2013-05-02 Pfizer Limited Chemical compounds
CN103958481B (en) 2011-10-28 2017-06-30 因西必泰克新有限公司 Can be used for the pyridyl derivatives treated
EP2791108B1 (en) 2011-12-15 2016-07-27 Pfizer Limited Sulfonamide derivatives
WO2013093688A1 (en) 2011-12-19 2013-06-27 Pfizer Limited Sulfonamide derivatives and use thereof as vgsc inhibitors
EP2800740A1 (en) 2012-01-04 2014-11-12 Pfizer Limited N-aminosulfonyl benzamides
ES2548228T3 (en) 2012-02-03 2015-10-15 Pfizer Inc Benzimidazole and imidazopyridine derivatives as sodium channel modulators
AU2013203824A1 (en) 2012-03-16 2013-10-03 Purdue Pharma L.P. Substituted pyridines and pryimidines as sodium channel blockers
MX366308B (en) * 2012-04-25 2019-07-04 Raqualia Pharma Inc Amide derivatives as ttx-s blockers.
CA2885247A1 (en) 2012-10-04 2014-04-10 Pfizer Limited Tropomyosin-related kinase inhibitors
JP2015531394A (en) 2012-10-04 2015-11-02 ファイザー・リミテッドPfizer Limited Pyrrolo [2,3-D] pyrimidine tropomyosin-related kinase inhibitor
EP2912036A1 (en) 2012-10-04 2015-09-02 Pfizer Limited Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
US9944634B2 (en) * 2012-10-31 2018-04-17 Raqualia Pharma Inc. Pyrazolopyridine derivatives as TTX-S blockers
EP2935257B1 (en) 2012-12-20 2018-02-07 Purdue Pharma LP Cyclic sulfonamides as sodium channel blockers
RU2683788C2 (en) 2013-01-31 2019-04-02 Вертекс Фармасьютикалз Инкорпорейтед Amides of quinoline and quinazoline, useful as a sodium channel modulators
BR112015018289A2 (en) * 2013-01-31 2017-07-18 Vertex Pharma pyridone amides as sodium channel modulators
SG11201507196WA (en) 2013-03-08 2015-10-29 Amgen Inc Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
AP2016009023A0 (en) 2013-07-19 2016-02-29 Vertex Pharma Sulfonamides as modulators of sodium channels
EP3560920A1 (en) 2013-10-15 2019-10-30 Janssen Pharmaceutica NV Secondary alcohol quinolinyl modulators of ror gamma t
US20160280691A1 (en) * 2013-11-07 2016-09-29 Biomarin Pharmaceutical Inc. Triazole intermediates useful in the synthesis of protected n-alkyltriazolecarbaldehydes
WO2015089361A1 (en) 2013-12-13 2015-06-18 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
JP2017526706A (en) * 2014-09-10 2017-09-14 エピザイム,インコーポレイティド Isoxazole carboxamide compounds
CN106674264A (en) * 2016-12-20 2017-05-17 苏州汉德创宏生化科技有限公司 Synthetic method for (2,2,2-trifluoroethoxyl) phenylboronic acid compounds
US11358977B2 (en) 2017-05-16 2022-06-14 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
UY37806A (en) 2017-07-11 2020-01-31 Vertex Pharma CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS
JP7269917B2 (en) * 2017-08-17 2023-05-09 イケナ オンコロジー, インコーポレイテッド AHR inhibitors and uses thereof
MX2020008082A (en) * 2018-02-05 2020-09-24 Univ Strasbourg Compounds and compositions for the treatment of pain.
JP2021512935A (en) 2018-02-12 2021-05-20 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated How to treat pain
CN109053434A (en) * 2018-07-18 2018-12-21 上海华堇生物技术有限责任公司 A kind of new preparation process of 2,4- dimethoxy-benzoyl chloride
CN108794328A (en) * 2018-08-03 2018-11-13 上海华堇生物技术有限责任公司 The preparation method of 3,4- dimethoxy-benzoyl chlorides
US20220110923A1 (en) 2019-01-10 2022-04-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020176763A1 (en) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
CN114269730A (en) 2019-08-06 2022-04-01 多曼治疗学公司 5-heteroaryl-pyridin-2-amine compounds as neuropeptide FF receptor antagonists
WO2021113627A1 (en) 2019-12-06 2021-06-10 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
CN113248455A (en) * 2021-05-25 2021-08-13 湖北科技学院 3, 5-disubstituted isoxazole derivatives and synthesis method thereof
BR112023025264A2 (en) 2021-06-04 2024-02-20 Vertex Pharma SOLID PHARMACEUTICAL FORMS AND DOSAGE REGIMES COMPRISING (2R,3S,4S,5R)-4-[[3- (3,4-DIFLUORO-2-METHOXY-PHENYL)-4,5-DIMETHYL-5-(TRIFLUOROMETHYL) TETRA- HYDROFURAN-2-CARBONYL]AMINO ]PYRIDINE-2-CARBOXAMIDE
EP4347033A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
WO2022256676A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
WO2022256702A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
TW202313593A (en) 2021-06-04 2023-04-01 美商維泰克斯製藥公司 N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
EP4347584A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
CN115703719A (en) * 2021-08-03 2023-02-17 联化科技股份有限公司 Preparation method of brominated oxime compound
WO2023205468A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
US20230373925A1 (en) 2022-04-22 2023-11-23 Vertex Pharma Heteroaryl compounds for the treatment of pain
WO2023205465A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
US20230382910A1 (en) 2022-04-22 2023-11-30 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9008022A (en) * 1990-05-18 1993-04-06 Hoechst Ag ISOXAZOL-4-CARBOXYLIC ACID STARCH AND HYDROXYALKYLIDIDEN-CYANACETIC ACID STARCHES, DRUGS CONTAINING THESE COMPOUNDS AND THEIR APPLICATION
WO1994014780A1 (en) 1992-12-18 1994-07-07 The Wellcome Foundation Limited Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors
AU4515896A (en) 1994-12-12 1996-07-03 Merck & Co., Inc. Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase
AU4515696A (en) 1994-12-12 1996-07-03 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
US6011051A (en) 1996-07-31 2000-01-04 Hoechst Aktiengesellschaft Use of isoxazole and crotonamide derivatives for the modulation of apoptosis
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US6060491A (en) * 1997-06-19 2000-05-09 Dupont Pharmaceuticals 6-membered aromatics as factor Xa inhibitors
DE19857009A1 (en) 1998-12-10 2000-06-15 Aventis Pharma Gmbh Preparation with improved therapeutic range, containing nucleotide synthesis inhibitors
US6458789B1 (en) 1999-09-29 2002-10-01 Lion Bioscience Ag 2-aminopyridine derivatives and combinatorial libraries thereof
GB0002666D0 (en) * 2000-02-04 2000-03-29 Univ London Blockade of voltage dependent sodium channels
AR029489A1 (en) 2000-03-10 2003-07-02 Euro Celtique Sa PIRIDINES, PYRIMIDINES, PIRAZINAS, TRIAZINES REPLACED BY ARILO, PHARMACEUTICAL COMPOSITIONS AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
AU5889701A (en) * 2000-06-05 2001-12-17 Dong A Pharm Co Ltd Novel oxazolidinone derivatives and a process for the preparation thereof
US6849660B1 (en) 2000-08-01 2005-02-01 Isis Pharmaceuticals, Inc. Antimicrobial biaryl compounds
DE10132308A1 (en) 2001-07-06 2003-01-30 Aventis Behring Gmbh Combination preparation for the therapy of immunological diseases
AR036873A1 (en) 2001-09-07 2004-10-13 Euro Celtique Sa PIRIDINAS ARIL REPLACED A, PHARMACEUTICAL COMPOSITIONS AND THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT
AR037233A1 (en) 2001-09-07 2004-11-03 Euro Celtique Sa PIRIDINAS ARIL REPLACED, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH COMPOUNDS FOR THE PREPARATION OF A MEDICINAL PRODUCT
JP2003086564A (en) * 2001-09-14 2003-03-20 Mitsubishi Electric Corp Centrifugal drier, semiconductor device manufacturing method and semiconductor manufacturing apparatus
DE60235114D1 (en) * 2001-11-01 2010-03-04 Icagen Inc PYRAZOLAMIDES FOR USE IN THE TREATMENT OF PAIN
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
PT1864975E (en) 2002-02-12 2010-12-27 Glaxosmithkline Llc Nicotinamide derivates useful as p38 inhibitors
EP1603897A1 (en) 2003-03-14 2005-12-14 Biolipox AB Pyrazole compounds useful in the treatment of inflammation
MXPA05012081A (en) 2003-05-09 2006-02-22 Pharmacia & Upjohn Co Llc Substituted pyrimidine derivatives.
MY142655A (en) 2003-06-12 2010-12-15 Euro Celtique Sa Therapeutic agents useful for treating pain
ATE412646T1 (en) 2003-09-22 2008-11-15 Euro Celtique Sa THERAPEUTIC AGENTS SUITABLE FOR THE TREATMENT OF PAIN
WO2005084368A2 (en) 2004-03-02 2005-09-15 Neurogen Corporation Heteroalkyl-substituted biphenyl-4-carboxylic acid arylamide analogues
BRPI0513717A (en) * 2004-07-23 2008-05-13 Pfizer pyridine derivatives
CA2585490A1 (en) 2004-11-12 2006-05-18 Galapagos Nv Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
US20060106011A1 (en) * 2004-11-12 2006-05-18 Bock Mark G 2-(Bicyclo)alkylamino-derivatives as mediators of chronic pain and inflammation
US8211919B2 (en) 2005-09-02 2012-07-03 Astellas Pharma Inc. Amide derivatives as rock inhibitors
MY145713A (en) 2005-09-09 2012-03-30 Smithkline Beecham Corp Hexahydropyrazino [2,1-c][1,4]oxazin-8(1h)-yl pyridine derivatives and their use in the treatment of psychotic disorders
EP1764093A1 (en) 2005-09-20 2007-03-21 Revotar Biopharmaceuticals AG Novel aromatic compounds and their use in medical applications
EP1764095A1 (en) 2005-09-20 2007-03-21 Revotar Biopharmaceuticals AG Novel nitrocatechol derivatives having selectin ligand activity
ES2274712B1 (en) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. NEW IMIDAZOPIRIDINE DERIVATIVES.
JP2009513691A (en) 2005-10-31 2009-04-02 バイオリポックス エービー Triazole compounds as lipoxygenase inhibitors
TW200732320A (en) 2005-10-31 2007-09-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
TWI385169B (en) * 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd Heterocyclic substituted pyridine derivatives and antifungal agent containing same
NL2000284C2 (en) 2005-11-04 2007-09-28 Pfizer Ltd Pyrazine derivatives.
ES2431388T3 (en) 2005-11-08 2013-11-26 Vertex Pharmaceuticals Incorporated Heterocyclic compound useful as an ATP-binding cassette transporter modulator
WO2007058990A2 (en) 2005-11-14 2007-05-24 Kemia, Inc. Therapy using cytokine inhibitors
EP1955697B1 (en) 2005-11-30 2012-05-02 Astellas Pharma Inc. 2-aminobenzamide derivatives as vanilloid receptor 1 (vr1) inhibitors useful for the treatment of pain or bladder function disorder
EP1984339A1 (en) 2006-01-23 2008-10-29 Pfizer Limited Pyridine derivatives as sodium channel modulators
JP2009528273A (en) 2006-01-25 2009-08-06 シンタ ファーマシューティカルズ コーポレーション Substituted biaryl compounds for inflammation and immune related uses
TW200800188A (en) 2006-01-31 2008-01-01 Synta Pharmaceuticals Corp Pyridylphenyl compounds for inflammation and immune-related uses
AU2007216247A1 (en) 2006-02-17 2007-08-23 Pfizer Limited 3 -deazapurine derivatives as TLR7 modulators
WO2007126957A2 (en) 2006-03-31 2007-11-08 Novartis Ag New compounds
PE20080906A1 (en) 2006-08-17 2008-07-05 Kemia Inc HETEROARYL DERIVATIVES AS CYTOKINE INHIBITORS
EP2125778A1 (en) 2006-12-22 2009-12-02 Millennium Pharmaceuticals, Inc. Certain pyrazoline derivatives with kinase inhibitory activity
US7759344B2 (en) 2007-01-09 2010-07-20 Amgen Inc. Bis-aryl amide derivatives and methods of use
CA2679659C (en) 2007-03-01 2016-01-19 Novartis Ag Pim kinase inhibitors and methods of their use
EP2155727A1 (en) 2007-05-03 2010-02-24 Pfizer Limited N-[6-amino-5-(phenyl)pyrazin-2-yl]-isoxazole-4-carboxamide derivatives and related compounds as nav1.8 channel modulators for the treatment of pain

Also Published As

Publication number Publication date
GT200900280A (en) 2011-08-29
TW200906403A (en) 2009-02-16
PA8779201A1 (en) 2009-01-23
CO6251367A2 (en) 2011-02-21
EA015952B1 (en) 2011-12-30
CR11061A (en) 2009-11-03
AP2516A (en) 2012-11-26
AR070636A1 (en) 2010-04-28
ES2398606T3 (en) 2013-03-20
JP4657384B2 (en) 2011-03-23
EP2183241A2 (en) 2010-05-12
NI200900192A (en) 2010-07-15
TWI375675B (en) 2012-11-01
BRPI0810202A2 (en) 2014-10-21
AU2008247102B2 (en) 2011-11-24
SV2009003400A (en) 2010-08-17
CU20090180A7 (en) 2011-05-27
CL2008001268A1 (en) 2008-11-03
US8134007B2 (en) 2012-03-13
KR20100007956A (en) 2010-01-22
CU23846B1 (en) 2012-10-15
JP2010526050A (en) 2010-07-29
EP2183241B1 (en) 2012-12-19
PE20090730A1 (en) 2009-07-11
NZ581614A (en) 2011-06-30
GEP20125379B (en) 2012-01-10
MX2009011816A (en) 2009-11-19
CA2684105C (en) 2011-09-06
WO2008135826A3 (en) 2009-02-05
UY31063A1 (en) 2009-01-05
EA200970913A1 (en) 2010-04-30
ZA200907609B (en) 2011-04-28
TN2009000450A1 (en) 2011-03-31
AU2008247102A1 (en) 2008-11-13
ECSP099710A (en) 2009-11-30
MA31419B1 (en) 2010-06-01
CA2684105A1 (en) 2008-11-13
WO2008135826A2 (en) 2008-11-13
AP2009005009A0 (en) 2009-10-31
US20090048306A1 (en) 2009-02-19
CN101675040A (en) 2010-03-17
DOP2009000254A (en) 2009-11-30

Similar Documents

Publication Publication Date Title
AP2516A (en) 2-Pyridine carboxamide derivatives as sodium channel modulators
IL201202A0 (en) Imidazolidine carboxamide derivatives as p2x7 modulators
IL193173A0 (en) 3-deazapurine derivatives as tlr7 modulators
HK1149756A1 (en) Isoxazolo-pyridine derivatives
HK1141008A1 (en) Purinyl derivatives and their use as potassium channel modulators
EP2120569A4 (en) Spirochromanon derivatives
IL192627A0 (en) Prolinamide derivatives as sodium channel modulators
IL206276A0 (en) Pyridine derivatives
IL202020A0 (en) Spiroindolinone derivatives
HK1147968A1 (en) Biphenylcarboxamide derivatives as hedgehog pathway modulators
ZA200905796B (en) Purinyl derivatives and their use as potassium channel modulators
IL193176A0 (en) Benzoyl-piperidine derivatives as 5ht2/d3 modulators
EP2178373A4 (en) Heterocycles as potassium channel modulators
EP2175728A4 (en) Sodium channel inhibitors
IL200618A0 (en) Aza-pyridopyrimidinone derivatives
HK1138852A1 (en) Indozalyl sulphonamide derivatives useful as glucocorticoid modulators
IL208837A0 (en) Novel heteroaryl carboxamide derivatives
ZA200806811B (en) 3-Deazapurine derivatives as TLR7 Modulators
EP2141168A4 (en) Heteroaryl derivatives
IL202667A0 (en) Isoxazole-imidazole derivatives
PT2220060T (en) Tetrahydrobenzothiazole derivatives
SI2170861T1 (en) Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
ZA201007615B (en) Aminopyridine derivatives
EP2133347A4 (en) 1-biarylazetidinone derivatives
HK1141009A1 (en) Sulfonyl-quinoline derivatives